The Food and Drug Administration (FDA) has proposed new naming policies for the distinct naming of biosimilars and biologics for rheumatoid arthritis treatment. The new draft guidance is called Nonproprietary Naming of Biological Products: Guidance for Industry and is available to view here.
Under the new policies, which will be designated and enforced by the FDA, separate and distinctive names will be required when it comes to biosimilars and biologic drugs. This will ensure that pharmaceutical companies are following regulations and will remain compliant when it comes to the naming and marketing of biosimilar medications. Continue reading
Arthritis Broadcast Network’s “CRA Interview Series 2015″ – Dr. Robert Ferrari: Choosing Wisely campaign
Today’s feature interview – Dr. Robert Ferrari
ABN reporters from Canada’s arthritis consumer organizations interviewed leading health professionals and researchers during last month’s CRA and AHPA annual meetings.
Beginning, March 9, feature interviews will be posted on the ABN YouTube channel http://bit.ly/ABNYouTube. Please help us raise awareness about the important work going on in Canada by sharing the interviews with your organizational and social networks.
About Robert Ferrari
Picture from: Dr. Robert Ferrari Professional Corp Facebook Page
Dr. Robert Ferrari has a degree of Doctor of Medicine (with Honors in Research) from the University of Alberta (1990), and completed his fellowship in Internal Medicine at the University of Alberta (Edmonton, Alberta) and Queen’s University (Kingston, Ontario) in 1994. He has a Master of Science degree in Experimental Medicine from the University of Alberta (2010). He is an Internist and practice Internal Medicine in Rheumatology in Edmonton, Alberta. Dr. Ferrari is a past recipient of the Canadian Rheumatology Association’s Young Investigator award. He currently serves as a member of the Choosing Wisely Committee for the Canadian Rheumatology Association.
About Choosing Wisely Canada
Choosing Wisely Canada (CWC) is a campaign to help physicians and patients engage in conversations about unnecessary tests, treatments and procedures, and to help physicians and patients make smart and effective choices to ensure high-quality care.
Unnecessary tests, treatments and procedures do not add value to care. In fact, they take away from care by potentially exposing patients to harm, leading to more testing to investigate false positives and contributing to stress for patients. And of course unnecessary tests, treatments and procedures put increased strain on the resources of our health care system.
Canadian national specialty societies participating in the campaign, representing a broad spectrum of physicians, have been asked to develop lists of “Five Things Physicians and Patients Should Question.” These lists identify tests, treatments or procedures commonly used in each specialty, but are not supported by evidence, and/or could expose patients to unnecessary harm.
My friend, her daughter and her 6-month old son recently came for an afternoon visit and while the baby entertained us with his antics, his shirt opened to reveal that he was wearing a necklace made of small amber beads.
The baby’s mother, a university-educated and grounded young woman, told me that many young babies wear these necklaces because it is believed that amber has strong anti-inflammatory and pain-relieving properties. Babies wear amber as a remedy for teething; Baltic amber, in particular, is thought to soothe and calm a fussy baby without resorting to drugs. Continue reading
Fran catching up on her online newspaper reading
A small pleasure—when time permits—is reading a daily newspaper back to front, rather than my usual online skim and swipe. I had time during my winter retreat in Southwest Florida to enjoy the local newspaper although that was a quick read because the news coverage is far below “acceptable”. So I treat the newspaper as what it truly is: a great source for local events and activities, and I read it for its entertainment value.
The JointHealth™ Report Card and Arthritis Medications Guide issue
While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In particular, advances in the area of disease-modifying anti-rheumatic medications (or “DMARDs”) and biologic response modifiers (or “biologics”) have radically changed health outcomes—for the better—of thousands of people living with a number of the more than 100 types of arthritis.
To ensure that all Canadians have access to the medications they need to treat their arthritis, Arthritis Consumer Experts (ACE) created the first JointHealth™ Report Card on Provincial Formulary Reimbursements for Biologic Response Modifiers in 2007. Serving as a way to keep Canadians aware of how well their province compares to the rest of Canada in its cost coverage of medications, the Report Card ranks publicly funded medication formularies based on the number of medically necessary biologic arthritis medications they list.
The Report Card is available online at jointhealth.org and updated monthly. Once a year, it is printed and distributed to JointHealth™ monthly readers and subscribers, elected officials, arthritis specialists and healthcare professionals across Canada.
Inside this issue of JointHealth™ monthly, in addition to the Report Card you will find:
- A chart listing important information about the medications used to treat arthritis in Canada, called the JointHealth™ Arthritis Medications Guide.
- An interview with Dr. Kam Shojania of the Arthritis Research Centre of Canada, in which he tells us about emerging medications for treating the most common forms of inflammatory and autoimmune arthritis.
- Details of ACE’s campaign to raise awareness about subsequent entry biologics (SEBs) in BC, Alberta, and Ontario.
- Information about exciting new research that was presented late last year in an annual conference that brings together researchers from around the world.